Literature DB >> 14569384

[Prostate carcinoma and erectile dysfunction. Which therapy when?].

H Sperling1, J Noldus.   

Abstract

The quality of life of patients after radical prostatectomy is mainly influenced by erectile dysfunction (ED) and incontinence. New criteria for treatment and patient selection give us the opportunity to restore sexual function in more patients. When ED is present, we should not wait for 24 months for natural restitution. PDE-5-inhibitors, intracavernosal self injection therapy and the vacuum constriction device are effective and conform to both patient and economic preference.Therefore, every urologists should be able to offer his patients an individual and successful approach to the therapy of ED after prostate cancer.

Entities:  

Mesh:

Year:  2003        PMID: 14569384     DOI: 10.1007/s00120-003-0416-2

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  21 in total

1.  Analysis of NOS isoform changes in a post radical prostatectomy model of erectile dysfunction.

Authors:  C A Podlasek; C M Gonzalez; D J Zelner; H B Jiang; K E McKenna; K T McVary
Journal:  Int J Impot Res       Date:  2001-12       Impact factor: 2.896

2.  Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial.

Authors:  F Montorsi; G Guazzoni; L F Strambi; L F Da Pozzo; L Nava; L Barbieri; P Rigatti; G Pizzini; A Miani
Journal:  J Urol       Date:  1997-10       Impact factor: 7.450

3.  [Potency-sparing radical perineal prostatectomy].

Authors:  G Jakse; B Brehmer; H Borchers; A Verger-Kuhnke; S Biesterfeld
Journal:  Urologe A       Date:  2003-01-15       Impact factor: 0.639

4.  Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'.

Authors:  M Braun; G Wassmer; T Klotz; B Reifenrath; M Mathers; U Engelmann
Journal:  Int J Impot Res       Date:  2000-12       Impact factor: 2.896

5.  Efficacy of sildenafil in erectile dysfunction after radical prostatectomy.

Authors:  D S Blander; R F Sanchez-Ortiz; A J Wein; G A Broderick
Journal:  Int J Impot Res       Date:  2000-06       Impact factor: 2.896

6.  Sequential administration enhances the effect of apomorphine SL in men with erectile dysfunction.

Authors:  J P W Heaton; J Dean; D J Sleep
Journal:  Int J Impot Res       Date:  2002-02       Impact factor: 2.896

7.  Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate (Viagra).

Authors:  C D Zippe; A W Kedia; K Kedia; D R Nelson; A Agarwal
Journal:  Urology       Date:  1998-12       Impact factor: 2.649

Review 8.  Erectile function after radical prostatectomy: a review.

Authors:  E J H Meuleman; P F A Mulders
Journal:  Eur Urol       Date:  2003-02       Impact factor: 20.096

9.  Patient reported sexual function following laparoscopic radical prostatectomy.

Authors:  Ran Katz; Laurent Salomon; Andras Hoznek; Alexandre de la Taille; Dimitrios Vordos; Antony Cicco; Dominique Chopin; Clement Claude Abbou
Journal:  J Urol       Date:  2002-11       Impact factor: 7.450

10.  Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy.

Authors:  R A Costabile; M Spevak; I J Fishman; F E Govier; W J Hellstrom; R Shabsigh; K J Nemo; J L Rapport; P Y Tam; K L Weldon; N Gesundheit
Journal:  J Urol       Date:  1998-10       Impact factor: 7.450

View more
  2 in total

Review 1.  [Structure and process quality of inpatient urologic rehabilitation].

Authors:  W Vahlensieck; M Gäck; J Gleissner; W Hoffmann; S Liedke; U Otto; D Sauerwein; E Schindler; H Schultheis; F Sommer; R Templin; M Zellner
Journal:  Urologe A       Date:  2005-01       Impact factor: 0.639

2.  [Erectile function after nerve-sparing radical prostatectomy. Nocturnal early erection as a parameter of postoperative organic erectile integrity].

Authors:  A Bannowsky; H Schulze; C van der Horst; J H Stübinger; F J Martinez Portillo; K P Jünemann
Journal:  Urologe A       Date:  2005-05       Impact factor: 0.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.